Alzheimer’s Disease Clinical Trial

Clinical Trial Evaluating the Safety and Efficacy of Pepinemab in People with Alzheimer’s Disease

NOW ENROLLING

Get More Information

Study assessments, testing and medication are provided at no cost to participants.
Participant stipend and travel reimbursement may be possible.

Do You or Someone You Love Have Alzheimer’s Disease?

Consider Participating in the SIGNAL-AD Trial

SIGNAL-AD is a clinical study of an investigational drug called pepinemab. Pepinemab works in a way that is different than other drugs being studied for Alzheimer’s disease and has been previously studied in people with Huntington’s disease, another neurodegenerative disorder. The study will evaluate the drug’s safety profile, brain imaging effects and potential effects on cognition in people with early Alzheimer’s disease.

You may be eligible if you:

  • Are 55 to 85 years old

  • Have been diagnosed with early Alzheimer’s disease

  • Have a trial partner who will support you and participate in the study

Interested in Participating in the Study or Would Like More Information?
Connect with a Study Center Near You

Your Name(Required)
Preferred form of communication:
Please tell us which locations you are interested in participating in:(Required)
(Must select at least one location)
This field is for validation purposes and should be left unchanged.

The map below can help you find a Study Center near you:

Search Location

Radius: KM
Loading...
Step 2: Choose a Study Location: 0 PRINT

Store Direction

Get Your Directions

Use my location to find the closest Service Provider near me

Trial Purpose

The purpose of the study is to investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in people with early Alzheimer’s disease dementia (early AD). The primary hypothesis being tested is whether pepinemab will be safe and provide benefits in clinical assessments of cognition and in brain metabolism as measured by FDG-PET.

Trial Details

About the Trial
The investigational drug (pepinemab) or placebo will be administered to study participants once each month by intravenous infusion. The study duration is 12 months.

Phase
Phase 1b/Phase 2

Enrollment Status
Active

Sponsor
Vaccinex, Inc.

Collaborators
Alzheimer’s Drug Discovery Foundation
Alzheimer’s Association

Download the Recruitment Flyer

PDF (262 kB)

Pepinemab is an investigational drug currently in clinical studies. It has not been demonstrated to be safe and effective for any disease indication, including Alzheimer’s disease. There is no guarantee that pepinemab will be approved for the treatment of any disease by the U.S. Food and Drug Administration or by any other health authority worldwide.

Learn more about Pepinemab at www.Vaccinex.com.